BioVeda Capital

Sensely is a company that develops a conversational platform aimed at enhancing the experience of insurance plan members and patients. By utilizing avatar and chatbot technology, Sensely's platform provides virtual assistant solutions for insurance companies, pharmaceutical clients, and hospital systems globally. This innovative approach allows enterprises to engage with their members in a more meaningful way, merging the empathy inherent in human conversation with the efficiency and scalability offered by technology. Through this platform, Sensely seeks to improve brand preference and influence user behavior, ultimately transforming the way healthcare organizations interact with their stakeholders.

CXA Group is an Insurtech start-up established in 2013, recognized as a leader in the Asian market with over 600 clients, including Fortune 500 companies. The company focuses on transforming employee benefits and workplace wellness by shifting the emphasis from treatment to prevention. Its innovative platform utilizes artificial intelligence to provide a fixed benefits wallet, allowing employees to select a tailored mix of insurance, wellness, and disease management services that best meet their individual needs. This approach not only empowers employees to manage their health proactively but also enables employers to access aggregated health and claims analytics. By doing so, organizations can identify and prioritize interventions that lower costs and enhance employee health, productivity, and engagement.

ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Singapore, focusing on developing innovative treatments in the fields of immunology and oncology. Founded in 2010, the company is dedicated to transforming the lives of patients through its clinical portfolio, which includes ASLAN004, a monoclonal therapy aimed at treating atopic dermatitis and other immunological conditions, as well as a small molecule inhibitor directed at oncology applications. ASLAN collaborates with several partners, enhancing its research and development efforts.

Biolidics Limited is a medical technology company based in Singapore that specializes in the development of cell enrichment systems for cancer-related applications, including diagnosis, prognosis, treatment selection, and monitoring. Founded in 2009, the company has created the ClearCell FX1 System, an automated in vitro diagnostic device designed to separate and enrich cancer cells from blood samples. Biolidics engages in research, development, and marketing in the fields of biotechnology, life sciences, and medical technology, serving a diverse clientele that includes academic institutions, hospitals, and laboratories across Singapore, China, Hong Kong, Japan, the United States, and European Union countries. The company also collaborates strategically with Sysmex Corporation and generates significant revenue from its laboratory services segment, which provides essential laboratory operations and services to various customers.

ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Singapore, focusing on developing innovative treatments in the fields of immunology and oncology. Founded in 2010, the company is dedicated to transforming the lives of patients through its clinical portfolio, which includes ASLAN004, a monoclonal therapy aimed at treating atopic dermatitis and other immunological conditions, as well as a small molecule inhibitor directed at oncology applications. ASLAN collaborates with several partners, enhancing its research and development efforts.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Inspired Capital plc is a financial services provider based in Bristol, United Kingdom, specializing in lending products tailored for small and medium-sized enterprises (SMEs). The company offers a range of financing solutions, including business cash, asset finance, trade finance, construction finance, recruitment finance, transport finance, enterprise finance guarantee, factoring, and invoice discounting. Inspired Capital aims to facilitate quick and efficient access to funding for small businesses, enabling them to grow, manage cash flow, and invest in new opportunities without unnecessary delays. Originally known as Renovo Group plc, the company rebranded in August 2014 and was taken private in August 2015.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Renovis, Inc. is a biopharmaceutical company focused on the development of drugs for neurological diseases and disorders. The company is actively working on treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing a range of scientific disciplines, including molecular biology, medicinal chemistry, pharmacology, drug metabolism, toxicology, and informatics, Renovis aims to identify and select small molecule drug candidates that adhere to rigorous development standards.

NewBiotics is a U.S.-based biotechnology company founded in 1997, specializing in the discovery and development of therapeutic agents that exploit drug resistance mechanisms in cancer and infectious diseases. The company focuses on creating drug molecules that can transform drug resistance into therapeutic advantages, utilizing Enzyme Catalyzed Therapeutic Agents in its research. Notably, NewBiotics has identified the presence of double-minute chromosomes, which are unique to cancer cells, and has developed technology for the purification of double minute DNA from tumor cells. In 2004, NewBiotics was acquired by Celmed Biosciences, further advancing its mission in the field of therapeutics.